Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its lead compound in cardioversion, AP30663. The results of the study demonstrated that intravenous AP30663 was well tolerated with ascending doses, with no significant adverse events.
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting an estimated 10 million people in the US and the EU (30 million people worldwide). The incidence of AF increases with age and it is estimated that 5-10% of the population above the age of 70 have AF.
Acesion’s novel approach is based on inhibition of SK channels – ion channels present in the atria where they play a role in regulating the cardiac rhythm. Blocking these ion channels with a functionally atrial selective drug helps avoid deleterious effects on the ventricles. Targeting the SK channels thereby constitutes a novel and promising approach for an effective treatment of AF with an expected higher cardiac safety profile.
Commenting on the news, Frans Wuite, CEO of Acesion Pharma said: “It is very exciting to see these promising Phase 1 results that indicate safety even at levels above expected therapeutic doses. This is an important milestone for AP30663 and validates the concept of SK-inhibition for atrial fibrillation and thereby the promise of Acesion‘s portfolio.
